On the discovery and development of CFTR chloride channel activators

Current Pharmaceutical Design

Volumn 12, Issue 4, 2006, Pages 471-484

  Becq, Frédéric ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

Activators; CFTR chloride channel; Cystic fibrosis; HTS; Pharmacology

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 1 (3 CHLOROPHENYL) 5 TRIFLUOROMETHYL 3 HYDROBENZIMIDAZOL 2 ONE; 1 (5 CHLORO 2 HYDROXYPHENYL) 5 TRIFLUOROMETHYL 2 BENZIMIDAZOLONE; 1 ETHYL 2 BENZIMIDAZOLINONE; 3,7 DIMETHYL 1 (2 PROPENYL)XANTHINE; 3,7 DIMETHYL 1 (OXIRANYLMETHYL)XANTHINE; 3,7 DIMETHYL 1 ISOBUTYLXANTHINE; 3,7 DIMETHYL 1 PROPYLXANTHINE; 4 BROMOLEVAMISOLE; 5,6 DICHLORO 1 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE TRIPHOSPHATE; ALPHA NAPHTHOFLAVONE DERIVATIVE; AMRINONE; APIGENIN; BENZIMIDAZOLE DERIVATIVE; CAFFEINE; CHLORIDE CHANNEL; CHLORIDE CHANNEL STIMULATING AGENT; FLAVONOID; GENISTEIN; ION TRANSPORT AFFECTING AGENT; ISOBUTYLMETHYLXANTHINE; LEVAMISOLE; MILRINONE; PHOSPHODIESTERASE INHIBITOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; UCCF 853; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CHLORIDE CHANNEL; X 31; X 32; X 33; X 34; XANTHINE DERIVATIVE; CHLOROPHENOL;

CHANNEL GATING; CYSTIC FIBROSIS; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HOMEOSTASIS; HUMAN; MOLECULAR CLONING; MUTATIONAL ANALYSIS; MYOTONIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; DRUG POTENTIATION; GENETICS; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

BENZIMIDAZOLES; CHLOROPHENOLS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DESIGN; FLAVONOIDS; HUMANS; ION CHANNEL GATING; MOLECULAR STRUCTURE; MUTATION;

EID: 33644930571     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775474459     Document Type: Review

References (90)

1. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-73.
2. Hanrahan JW, Gentzsch M, Riordan JR. The Cystic Fibrosis Transmembrane Conductance Regulator (ABCC7). In: Holland IB, Cole S, Kuchler K, Higgins CF editors. ABC Proteins: From Bacteria to Man. Academic Press 2003; pp. 589-618.
3. Ratjen F, Doring G. Cystic Fibrosis. Lancet 2003; 361: 681-89.
4. Tabcharani JA, Chang X-B, Riordan JR, Hanrahan JW. Phosphorylation-regulated Cl- channel in CHO cells stably expressing the cystic fibrosis gene. Nature 1991; 352: 628-31.
5. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999; 79: 23-45.
6. Gadsby DC, Nairn AC. Contol of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol Rev 1999; 79: 77-107.
7. Anderson MP, Berger HA, Rich DP, Gregory RJ, Smith AE, Welsh MJ. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 1991; 67: 775-84.
8. Baukrowitz T, Hwang TC, Nairn AC, Gadsby DC. Coupling of CFTR Cl channel gating to an ATP hydrolysis cycle. Neuron 1994; 12: 473-82.
9. Gray MA, Greenwell JR, Argent BE. Secretin-regulated chloride channel on the apical plasma membrane of pancreatic duct cells. J Membr Biol 1988; 105: 131-42.
10. 1 receptors by VIP and PACAP-27 in human bronchial epithelial cells induces CFTR-dependent chloride secretion. Brit J Pharm 2004; 14: 698-708.
11. Schwiebert EM, Benos DJ, Egan ME, Stutts J, Guggino WB. CFTR is a conductance regulator as well as a chloride channel Physiol Rev 1999; 79: 145-66.
12. Reddy MM, Light MJ, Quinton PM. Activation of the epithelial Na+ channel (EnaC) requires CFTR Cl channel function. Nature 1999; 402: 301-4.
13. - channel and CFTR-associated ATP channel: distinct pores regulated by common gates. EMBO J 1998; 17: 898-908.
14. Quinton PM. Physiological Basis of Cystic Fibrosis: A Historical Perspective. Physiol Rev 1999; 79: 3-22.
15. Linton KJ, Rosenberg MF, Kerr ID, Higgins CF. Structure of ABC Transporters. In: Holland IB, Cole S, Kuchler K, Higgins CF editors. ABC Proteins: From Bacteria to Man. Academic Press 2003; pp. 65-80.
16. Dawson DC, Smith SS, Mansoura MK. CFTR: mechanism of anion conduction. Physiol Rev 1999; 79: S47-75.
17. Chappe V, Hinkson DA, Howell LD, Evagelidis A, Liao J, Chang XB, et al. Stimulatory and inhibitory protein kinase C consensus sequences regulate the cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci USA 2004; 101: 390-95.
18. Becq F, Jensen TJ, Chang X-B, Savoia A, Rommens JM, Tsui L-C, et al. Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc Natl Acad Sci USA 1994; 91: 9160-64.
19. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73: 1251-4.
20. Cutting GR, Kasch LM, Rosenstein BJ, Zielensky J, Tsui L-C, Antonarakis SE, et al. A cluster of Cystic Fibrosis mutations in the first nucleotide binding fold domain of the Cystic Fibrosis conductance regulator protein. Nature 1990, 346: 366-9.
21. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990; 63: 827-34
22. Drumm ML, Wilkinson DJ, Smit LS, Worrell RT, Strong TV, Frizzell RA, et al. Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science 1991; 254: 1797-9.
23. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, et al. Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation. Nature 1991; 354: 526-28.
24. Al-Nakkash L, Hwang T-C. Activation of wild-type and DF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms. Pflügers Arch Eur J Physiol 1999; 437: 553-61.
25. Logan J, Hiestand D, Daram P, Huang Z, Muccio DD, Hartman J, et al. Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding. J Clin Invest 1994; 94: 228-36.
26. Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ. Mutations in CFTR associated with mild-disease-form Cl- channels with altered pore properties. Nature 1993; 362: 160-4.
27. Becq F, Fanjul M, Merten M, Figarella C, Hollande E, Gola M. Possible regulation of CFTR-chloride channels by membrane-bound phosphatases in pancreatic duct cells. FEBS Lett 1993; 327: 337-42.
28. 2+ -independent activation of cystic fibrosis transmembrane conductance regulator channels by phenylimidazothiazole drugs. J Biol Chem 1996; 271: 16171-79.
29. Eidelman O, Guay-Broder C, van Galen PJM, Jacobson KA, Fox C, Turner RJ, et al. A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc Natl Acad Sci USA 1992; 89: 5562-66.
30. Jacobson KA, Guay-Broder C, van Galen PJ, Gallo-Rodriguez C, Melman N, Jacobson MA, et al. Stimulation by alkylxanthines of chloride effelux in CFPAC-1 cells does not involve A1 adenosine receptors. Biochemistry 1995; 34: 9088-94.
31. Gribkoff VK, Champigny G, Babry P, Dworetzky SI, Meanwell NA, Lazdunski M. The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. J Biol Chem 1994; 269: 10983-86.
32. Olesen SP, Munch E, Moldt P, Drejer J. Selective activation of Ca2+-dependent K+ channels by novel benzimidazolone. Eur J Pharmacol 1994; 251: 53-9.
33. Illek B, Fischer H, Santos GF, Widdicombe JH, Machen TE, Reenstra WW. cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein. Am J Physiol 1995; 268: 886-93.
34. Illek B, Fischer H, Machen T. Alternate stimulation of apical CFTR by genistein in epithelia. Am J Physiol 1996; 270: 265-75.
35. He Z, Raman S, Guo Y, Reenstra W. Cystic fibrosis transmembrane conductance regulator activation by cAMP-independent mechanisms. Am J Physiol 1998; 275: 958-66.
36. Reenstra WW, Yurko-Mauro K, Dam A, Rama S, Shorten S. CFTR chloride channel activation by genistein: the role of serine/threonine protein phosphatases. Am J Physiol 1996; 271: 650-7.
37. Lansdell KA, Cai Z, Kidd JF, Sheppard DN. Two mechanisms of genistein inhibition of cystic fibrosis transmembrane conductance regulator Cl channels expressed in murine cell line. J Physiol 2000; 524: 317-30.
38. Dérand R, Bulteau-Pignoux L, Becq F. The cystic fibrosis mutation G551D alters the non-Michaelis-Menten behavior of the cystic fibrosis transmembrane conductance regulator (CFTR) channel and abolishes the inhibitory Genistein binding site. J Biol Chem 2002; 277: 35999-6004.
39. Melin P, Thoreau V, Norez C, Bilan F, Kitzis A, Becq F. The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein. Biochem Pharmacol 2004; in press.
40. Becq F, Mettey Y, Gray MA, Galietta LJV, Dormer RL, Merten M, et al. Development of substituted benzo[c]quinolizinium compounds as novel activators of the Cystic Fibrosis Chloride Channel. J Biol Chem 1999; 274: 27415-25.
41. Denyer J, Worley J, Cox B, Allenby G, Banks M. HTS approaches to voltage-gated ion channel drug discovery. Drug Disco Today 1998; 3: 323-32.
42. Xu J, Wang X, Ensign B, Li M, Wu L, Guia A, et al. Ion-channel assay technologies: quo vadis? Drug Disco Today 201; 6: 1278-87.
43. Verkman AS. Drug discovery in academia. Am J Physiol 2004; 286: 465-474.
44. Willumsen NJ, Bech M, Olesen S-P, Jensen BS, Korsgaard MPG, Christophersen P. High throughput electrophysiology: new perspectives for ion channel drug discovery. Receptor Channels 2003; 9: 3-12.
45. Terstappen GC. Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium effelux assay. Anal Biochem 1999; 272: 149-55.
46. Marivingt-Mounir C, Norez C, Dérand R, Bulteau-Pignoux L, Nguyen-Huy D, Viossat B, et al. Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels. J Med Chem 2004; 47: 962-72.
47. Ma T, Vetrivel L, Yang H, Pedemonte N, Zegarra-Moran O, Galietta LJV, et al. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-troughput screening. J Biol Chem 2002; 277: 37235-41.
48. Mahlangu DA, Dix JA. Halide fluxes in epithelial cells measured with an automated cell plate reader. Anal Biochem 2004; 325: 28-34.
49. Venglarik CJ, Bridges RJ, Frizzell RA. A simple assay for agonist-regulated Cl and K conductances in salt-secreting epithelial cells. Am J Physiol 1990; 259: 358-64.
50. Dormer RL, Dérand R, McNeilly C, Mettey Y, Dérand R, Bulteau L, et al. Correction of delF508-CFTR activity with benzoquinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J Cell Sci 2001; 114: 4073-81.
51. Chappe V, Mettey Y, Vierfond J-M, Hanrahan JW, Gola M, Verrier B, et al. Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel. Br J Pharmacol 1998; 123: 683-93.
52. Bulteau L, Dérand R, Mettey Y, Métayé T, Morris MR, McNeilly CM, et al. Properties of CFTR activated by the xanthine derivative X-33 in human airway Calu-3 cells. Am J Physiol 2000; 279: 1925-37.
53. Cohen BE, Lee G, Jacobson KA, Kim YC, Huang Z, Sorscher EJ, et al. 8-cyclopentyl-1-3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry 1997; 36: 6455-61.
54. Kelley TJ, Al-Nakkash L, Cotton CU, Drumm ML. Activation of endogenous DF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J Clin Invest 1996; 98: 513-20.
55. Kelley TJ, Thomas K, Milgram LJH, Drumm ML. In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant DF508 in murine nasal epithelium. Proc Natl Acad Sci USA 1997; 94: 2604-8.
56. Smith SN, Middleton PG, Chadwick S, Jaffe A, Bush KA, Rolleston S, et al. The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. Am J Respir Cell Mol Biol 1999; 20: 129-34.
57. O'Grady SM, Jiang X, Maniak PJ, Birmachu W, Scribner LR, Bulbulian B, et al. Cyclic AMP-dependent Cl secretion is regulated by multiple phosphodiesterase subtypes in human colonic epithelial cells. J Memb Biol 2002; 185: 137-44.
58. - secretion by benzimidazolones. II. Coordinate regulation of apical GCl and basolateral GK. Am J Physiol 1996; 271: 785-95.
59. Dérand R, Bulteau-Pignoux L, Becq F. Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J Membr Biol 2003; 194: 109-17.
60. - channel activity compensates for defective processing in a cystic fibrosis mutant corresponding to a mild form of the disease. EMBO J 1995; 14: 2417-23.
61. Al-Nakkash L, Hu S, Li M, Hwang T-C. A common mechanism for cystic fibrosis transmembrane conductance regulator protein activation by genistein and benzimidazolone analogues. J Pharm Exp Ther 2001; 296: 464-72.
62. Singh S, Syme CA, Singh AK, Devor DC, Bridges RJ. Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J Pharm Exp Ther 2001; 296: 600-11.
63. Caci E, Folli C, Zegarra-Moran O, Ma T, Springsteel W, Sammelson RE, et al. CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. Am J Physiol 2003; 285: 180-8.
64. Galietta LJV, Springsteel MF, Eda M, Niedzinski EJ, By K, Haddadin MJ, et al. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 2001; 276: 19723-8.
65. Randak C, Auerswald EA, Assfalg-Machleidt I, Reenstra WW, Machleidt W. Inhibition of ATPase, GTPase and adenylate kinase activities of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator by genistein. Biochem J 1999; 340: 227-35.
66. Howell LD, Borchardt R, Cohn JA. ATP hydrolysis by a CFTR domain: pharmacology and effects of G551D mutation. Biochem Biophys Res Commun 2000; 271: 518-25.
67. Luo J, Zhu T, Evagelidis A, Pato MD, Hanrahan JW. Role of protein phosphatases in the activation of CFTR (ABCC7) by genistein and bromotetramisole. Am J Physiol 2000; 279: 108-19.
68. Wang F, Zeltwanger S, Yang IC, Nairn AC, Hwang T-C. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J Gen Physiol 1998; 111: 477-90.
69. Illek B, Zhang L, Lewis NC, Moss RB, Dong JY, Fischer H. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol 1999; 277: 833-9.
70. Springsteel MF, Galietta LJV, Ma T, By K, Berger GO, Yang H, et al. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorg Med Chem 2003; 11: 4113-20.
71. Dérand R, Bulteau-Pignoux L, Mettey Y, Zegarra-Moran O, Howell LD, Randak C, et al. Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phosphorylation. Am J Physiol 2001; 281: 1657-66.
72. Stratford FLL, Pereira MMC, Becq F, McPherson MA, Dormer RL. Benzo(c) quinolizinium, drugs inhibit degradation of ΔF508-CFTR cytoplamsic domain. Biochem Bioph Res Com 2003; 300: 524-30.
73. + channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents. J Gen Physiol 1992; 100: 573-91.
74. + channels by substituted benzo[c]quinolizinium CFTR activators. Biochem Pharm 2003; 66: 425-30.
75. Duszyk M, Mac Vinish L, Cuthbert AW. Phenanthrolines-a new class of CFTR chloride channel openers. Br J Pharmacol 2001; 134: 853-64.
76. Cuthbert AW. Benzoquinolines and chloride secretion in murine colonic epithelium. Br J Pharmacol 2003; 138: 1528-34.
77. Cuthbert AW, MacVinish LJ. Mechanisms of anion secretion in Calu-3 human airway epithelial cells by 7, 8-benzoquinoline. Br J Pharmacol 2003, 140: 81-90.
78. + channels by fluorescein derivatives. J Biol Chem 1992; 267: 4557-63.
79. - current by phloxine B. Br J Pharmacol 2000; 131: 433-40.
80. Cai Z, Sheppard DN. Phloxine B interacts with the cystic fibrosis transmembrane conductance regulator at multiple sites to modulate channel activity. J Biol Chem 2002; 277: 19546-53.
81. Sammelson RE, Ma T, Galietta LJV, Verkman AS, Kurth MJ. 3-(2-benzyphenyl) isoxazoles and isoxazolines: synthesis and evaluation as CFTR activators. Bioorg Med Chem Lett 2003; 13: 2509-12.
82. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, et al. Nanomolar affinity small molecule correctors of defective DF508-CFTR chloride channel gating. J Biol Chem 2003; 278: 35079-85.
83. - secretion by chlorzoxazone. J Pharm Exp Ther 2000; 292: 778-87.
84. - secretion. Am J Physiol 1997; 272: 976-88.
85. Mazzei M, Nieddu E, Folli C, Caci E, Galietta LJV. 2-(dialkylamino)-4H-1-benzopyran-4-one derivatives modify chloride conductance in CFTR expressing cells. Il Farmaco 2003; 58: 961-70.
86. Marcet B, Becq F, Norez C, Delmas P, Verrier B. General anesthetic octanol and related compounds activate wild-type and delF508 cystic fibrosis chloride channels. Brit J Pharm 2004; 141: 905-14.
87. Fischer H, Schwarzer C, Illek B. Vitamin C controls the cystic fibrosis transmembrane conductance regulator chloride channel. Proc Natl Acad Sci USA 2004; 101: 3691-96.
88. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adin J. Ion channels and epilepsy. Curr Pharm Design 2005; 11(15):1975-2003.
89. Johnston GA. GABA(A) receptor channel pharmacology. Curr Pharm Design 2005; 11(15): 1867-85.
90. See F, Kompa A, Martin J, Lewis DA, Krum H. Fibrosis as a therapeutic target post-myocardial infarction. Curr Pharm Design 2005; 11(4): 477-87